Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;109(5):526-541.
doi: 10.1111/ejh.13841. Epub 2022 Aug 26.

Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study

Sarah Friis Christensen  1 , Lise Skovgaard Svingel  2 , Anders Kjaersgaard  2 , Anna Stenling  3 , Bianka Darvalics  2 , Björn Paulsson  3 , Christen Lykkegaard Andersen  4   5 , Christian Fynbo Christiansen  2 , Jesper Stentoft  6 , Jørn Starklint  7 , Marianne Tang Severinsen  8 , Mette Borg Clausen  4 , Morten Hagemann Hilsøe  9 , Hans Carl Hasselbalch  1 , Henrik Frederiksen  10 , Ellen Margrethe Mikkelsen  2 , Marie Bak  1   4
Affiliations

Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study

Sarah Friis Christensen et al. Eur J Haematol. 2022 Nov.

Abstract

Few studies have assessed healthcare resource utilization (HRU) in patients with Philadelphia-negative myeloproliferative neoplasms (MPN) using a matched cohort design. Further, no detailed assessment of HRU in the years preceding an MPN diagnosis exists. We conducted a registry-based nationwide Danish cohort study, including patients with essential thrombocythemia, polycythemia vera, myelofibrosis, and unclassifiable MPN diagnosed between January 2010 and December 2016. HRU data were summarized annually from 2 years before MPN diagnosis until emigration, death, or end of study (December 2017). We included 3342 MPN patients and 32 737 comparisons without an MPN diagnosis, matched on sex, age, region of residence, and level of education. During the study period, the difference in HRU (rate ratio) between patients and matched comparisons ranged from 1.0 to 1.5 for general practitioner contacts, 0.9 to 2.2 for hospitalizations, 0.9 to 3.8 for inpatient days, 1.0 to 4.0 for outpatient visits, 1.3 to 2.1 for emergency department visits, and 1.0 to 4.1 for treatments/examinations. In conclusion, MPN patients had overall higher HRU than the matched comparisons throughout the follow-up period (maximum 8 years). Further, MPN patients had substantially increased HRU in both the primary and secondary healthcare sector in the 2 years preceding the diagnosis.

Keywords: ambulatory care; case-control studies; early diagnosis; epidemiology; general practice; health resources; healthcare costs; hospitalization; myeloproliferative disorder; registries.

PubMed Disclaimer

Conflict of interest statement

Novartis funded the work done by the employees at Aarhus University. Anders Kjærsgaard, Bianka Darvalics, Christian Fynbo Christiansen, Ellen Margrethe Mikkelsen, and Lise Skovgaard Svingel: employees at Aarhus University. Anna Stenling and Björn Paulsson: employees at Novartis. Hans Carl Hasselbalch: consultant for Novartis. All authors declare no personal competing interests.

Figures

FIGURE 1
FIGURE 1
Rate ratios of healthcare resource utilization between ET, PV, MF, and MPN‐U patients and their comparisons. comp, comparisons; ET, essential thrombocythemia; HRU, healthcare resource utilization; MPN, myeloproliferative neoplasms; MPN‐U, unclassifiable myeloproliferative neoplasm; MF, myelofibrosis; pt, patients; PV, polycythemia vera
See this image and copyright information in PMC

References

    1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391‐2406. - PubMed
    1. Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes. Blood. 2017;130(23):2475‐2483. - PubMed
    1. Geyer HL, Dueck AC, Scherber RM, Mesa RA. Impact of inflammation on myeloproliferative neoplasm symptom development. Mediators Inflamm [Internet]. 2015;284706. 10.1155/2015/284706 - DOI - PMC - PubMed
    1. Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017;4:2168‐2181. - PubMed
    1. Landtblom AR, Andersson TM‐L, Dickman PW, Smedby KE, Eloranta S, Batyrbekova N, Samuelsson J, Björkholm M, Hultcrantz M Risk of infections in patients with myeloproliferative neoplasms—a population‐based cohort study of 8363 patients. Leukemia [Internet] 2021;35(2):476–84. 10.1038/s41375-020-0909-7 - DOI - PMC - PubMed

MeSH terms

Grants and funding